Coronaviruses are enveloped RNA viruses that are characterized by their crown of club-shaped peplomers (spikes). According to the CDC, there are seven coronaviruses that cause illness in humans. Of these, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) initially only infected animals but adapted to cause illness in humans. SARS-CoV-2 is the most recent of these coronaviruses identified, emerging in Wuhan, China, in December 2019. The outbreak of this pathogen has since spread throughout the world, resulting in a devastating pandemic that continues to rage.
As in previous public health emergencies—such as Zika, SARS-CoV, MERS-CoV, and the Influenza A H1N1 2009 pandemic—ATCC is ready to partner with the global scientific community to prevent and contain this devastating outbreak. To assist in this endeavor, we offer researchers a range of tools and resources to contain the impact and investigate the long-lasting effects of the coronavirus disease, COVID-19.
- Heat-inactivated material for use in molecular assays or as a process control
- Genomic RNA prepared from clinical isolates, including recent variants of interest
- Synthetically derived RNA that are safe to use in BSL-1 facilities
- Whole-genome sequencing data for SARS-CoV-2 strains on the ATCC Genome Portal
- Polyclonal antibodies prepared against the spike glycoprotein of SARS-CoV-2 strain Wuhan-Hu-1
- Monoclonal antibodies against the full-length spike protein and spike glycoprotein receptor binding domain of SARS-CoV-2
- Microbial strains for cross-reactivity testing
- Cell lines for virus growth, vaccine development, respiratory studies, and immune research
View our resources below to discover how we can support your work toward the development of novel diagnostics and effective therapeutics.
Watch our webinar about credible solutions for critical public health emergencies
SARS-CoV-2 Molecular Diagnostics Development
The highly pathogenic nature and transmission dynamics of SARS-CoV-2 have necessitated the availability of rapid, robust detection methods to ensure that infected individuals are treated in a timely manner. For SARS-CoV-2 molecular diagnostics manufacturers moving from emergency use authorization (EUA) to 510(k) premarket submission to the US Food & Drug Administration (FDA), robust testing must be performed to demonstrate that the device is safe and effective as well as substantially equivalent to legally marketed devices. To support these validation studies, ATCC provides an extensive array of authenticated and clinically relevant materials for evaluating limit of detection, inclusivity, and cross-reactivity.Develop your SARS-CoV-2 assay